These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38174805)

  • 1. Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections.
    van Os W; Zeitlinger M
    J Antimicrob Chemother; 2024 Feb; 79(2):443-446. PubMed ID: 38174805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
    Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
    Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
    Paukner S; Goldberg L; Alexander E; Das AF; Heinrich S; Patel P; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Schranz J
    J Glob Antimicrob Resist; 2022 Jun; 29():434-443. PubMed ID: 34788694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms.
    Paukner S; Mendes RE; Arends SJR; Gassner G; Gelone SP; Sader HS
    J Antimicrob Chemother; 2024 Feb; 79(2):360-369. PubMed ID: 38113528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia.
    Lee YR; Jacobs KL
    Drugs; 2019 Nov; 79(17):1867-1876. PubMed ID: 31705486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin.
    Rodvold KA
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii2-iii4. PubMed ID: 30949709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
    Veve MP; Wagner JL
    Pharmacotherapy; 2018 Sep; 38(9):935-946. PubMed ID: 30019769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.
    Watkins RR; File TM
    Clin Infect Dis; 2020 Dec; 71(10):2757-2762. PubMed ID: 32221520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline.
    Dillon C; Guarascio AJ; Covvey JR
    Expert Rev Anti Infect Ther; 2019 Jan; 17(1):5-15. PubMed ID: 30513017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
    File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB
    Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Newly Approved Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: Lefamulin.
    Wang H; Charles CV
    Sr Care Pharm; 2020 Aug; 35(8):349-354. PubMed ID: 32718391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
    File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
    BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lefamulin: The First Systemic Pleuromutilin Antibiotic.
    Chahine EB; Sucher AJ
    Ann Pharmacother; 2020 Dec; 54(12):1203-1214. PubMed ID: 32493034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria.
    Paukner S; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Yu K
    Future Microbiol; 2022 Apr; 17(6):397-410. PubMed ID: 35285291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of lefamulin: A first-in-class semisynthetic pleuromutilin antibiotic.
    Covvey JR; Guarascio AJ
    J Intern Med; 2022 Jan; 291(1):51-63. PubMed ID: 34425035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).
    Paukner S; Gelone SP; Arends SJR; Flamm RK; Sader HS
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae.
    Wicha WW; Strickmann DB; Paukner S
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii11-iii18. PubMed ID: 30949707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
    Tang HJ; Wang JH; Lai CC
    Medicine (Baltimore); 2020 Jul; 99(29):e21223. PubMed ID: 32702892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis.
    Sawicki GS; Wicha WW; Hiley TS; Close NC; Gelone SP; Guico-Pabia CJ
    Clin Ther; 2024 Feb; 46(2):96-103. PubMed ID: 38195348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.